Exclusive: Time to Buy Cellectis SA (ADR) After Achieving 52-Week Low?

Exclusive: Time to Buy Cellectis SA (ADR) After Achieving 52 Week Low?

The stock of Cellectis SA (ADR) (NASDAQ:CLLS) hit a new 52-week low and has $15.44 target or 7.00% below today’s $16.60 share price. The 9 months bearish chart indicates high risk for the $579.10 million company. The 1-year low was reported on Nov, 7 by Barchart.com. If the $15.44 price target is reached, the company will be worth $40.54 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 80,642 shares traded hands. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 41.03% since April 5, 2016 and is downtrending. It has underperformed by 42.99% the S&P500.

According to Zacks Investment Research, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.”

More recent Cellectis SA (ADR) (NASDAQ:CLLS) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 21, 2015. Also Marketwatch.com published the news titled: “Plus the latest data from Realtor.com on 21 home markets across the US” on March 25, 2015. Schaeffersresearch.com‘s news article titled: “Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough” with publication date: May 06, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment